Results 41 to 50 of about 370,070 (295)
Advanced Science, EarlyView.This work identified CPD3a as a potent, stable C‐nucleoside cordycepin derivative. When formulated into microneedle array for topical treatment, it ameliorated psoriasis by rebalancing immunity and enhancing antioxidant defenses. ABSTRACT Psoriasis is a chronic inflammatory disorder characterized by immune dysregulation and epidermal hyperplasia ...
Wenfang Pan +7 more
wiley +1 more source
Primary cutaneous follicle center lymphoma [PDF]
, 2016 Cutaneous lymphomas are classified according to their cellular origin into T-cell lymphoma and B-cell lymphoma. The annual incidence rate is 0.3 per 100,000 population. We report a case of a 56-year-old male patient who presented with a two-month history
Eline Pinheiro Weba Costa +17 more
core +1 more source
Advanced Science, EarlyView.This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang +5 more
wiley +1 more source
Frontiers in ImmunologyRecent advances in molecular and immunologic profiling have substantially refined the understanding of mycosis fungoides (MF) and Sézary syndrome (SS), the two most prominent subtypes of cutaneous T-cell lymphomas (CTCL).
Anna Sophia Flechtenmacher +8 more
doaj +1 more source
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
Advanced Science, EarlyView.This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li +11 more
wiley +1 more source
CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation
Advanced Science, EarlyView.CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu +6 more
wiley +1 more source
, 2023 Chaninan Kositkuljorn,1 Suthinee Rutnin,1 Teerapong Rattananukrom,1 Teeraya Puavilai,2 Burana Khiankaew,3 Paisarn Boonsakan,3 Wimolsiri Iamsumang1 1Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol ...
Boonsakan P +6 more
core
Arthritis &Rheumatology, EarlyView.Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Primary cutaneous marginal-zone lymphoma [PDF]
, 2016 Primary cutaneous B cell lymphomas (PCBCL) are thesecond most common type of primary cutaneouslymphoma. The three main types of PCBCL areprimary cutaneous marginal-zone lymphoma(PCMZL), primary cutaneous follicle-centerlymphoma, and primary cutaneous ...
Farhadian, Joshua +3 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller +9 more
wiley +1 more source